Citigroup Maintains Buy on Lexicon Pharmaceuticals, Raises Price Target to $3.1

Citigroup analyst Yigal Nochomovitz maintains Lexicon Pharmaceuticals (NASDAQ:LXRX) with a Buy and raises the price target from $2.3 to $3.1.